Skip to main content
All lobbying filings

TIBER CREEK GROUP

TIBER CREEK GROUP filed a Q1 report for TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) on April 18, 2026, reporting $80,000 in lobbying income.

Lobbying for TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Pharmaceutical company.

All filings by TIBER CREEK GROUP · Everything TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 18, 2026
Income
$80,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025; Issues related to FDA guidance on Alcohol Use Disorder (AUD).

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.

 Bills named in this filing 3
  • H.R. 6509
    SAFE Drugs Act of 2025
  • S. 1041
    Affordable Prescriptions for Patients Act
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem